A subtractive genomic approach has been utilized for the identification of potential drug targets and vaccine candidates in Clostridium botulinum, the causative agent of flaccid paralysis in humans. The emergence of drug-resistant pathogenic strains has become a significant global public health threat. Treatment with antitoxin can target the neurotoxin at the extracellular level, however, can't converse the paralysis caused by botulism. Therefore, identification of drug targets and vaccine candidates in C. botulinum would be crucial to overcome drug resistance to existing antibiotic therapy. A total of 1729 crucial proteins, including chokepoint, virulence, plasmid and resistance proteins were mined and used for subtractive channel of analysis. This analysis disclosed 15 potential targets, which were non-similar to human, gut micro flora, and anti-targets in the host. The cellular localization of 6 targets was observed in the cytoplasm and might be used as a drug target, whereas 9 targets were localized in extracellular and membrane bound proteins and can be used as vaccine candidates. Furthermore, 4 targets were observed to be homologous to more than 75 pathogens and hence are considered as broad-spectrum antibiotic targets. The identified drug and vaccine targets in this study would be useful in the design and discovery of novel therapeutic compounds against botulism.
Background:
Botulism is a rare disease occurring worldwide and is caused by botulinum toxin made by Clostridium botulinum bacteria. This disease is hard to control due to the emergence of drug-resistant pathogenic strains. Present treatment use antitoxin, which can target the neurotoxin at the extracellular level, however, can't converse the paralysis caused by botulism. To combat the current state, discovery of new drug targets is needed, which is known as the first step in the drug discovery process [1] . Traditional methods of drug target identifications are time consuming and overpriced, which cannot fight effectively against the rapidly growing multidrug-resistant bacteria. The success of human genome project as well as sequencing of many pathogenic bacteria has provided sufficient data that can be used to predict drug and vaccines targets using in-Silico approach [2, 3] . A subtractive genomics method along with Bioinformatics analysis is widely used approach for the drug target prediction [4] . This has open new routes for the identification of potential therapeutic candidates, which has accelerated the drug discovery process, maximizes the treatment alternatives and reduced the drug failure rate in the later phase of clinical trials saving lots of money. In the last decades, a subtractive genomics approach has been effectively used to predict drug targets in Pseudomonas aeruginosa [5] , Mycobacterium tuberculosis [6] , and Salmonella enterica [7] . The similar subtractive genomic approach has adopted in this study to predict potential drug and vaccine targets in C. botulinum, where pathogen-specific, essential proteins were mined from the analysis of chokepoint, pathway, plasmid, virulence and resistance proteins. Moreover, the subtraction dataset between the host and the pathogen genome offers a set of genes that are likely to be important to the pathogen but absent in the host. The identified pathogen-specific proteins have the potential to become a good target and might be used in the drug discovery process.
Figure 1:
Flowchart describing the comprehensive methodology for the identification of potential targets, including drug and vaccine using subtractive genomics approach.
Methodology:
The probable drug targets in C. botulinum (strain Hall/ ATCC 3502/ NCTC 13319/ Type A) was identified through the subtractive genomics approach, including I) mining of essential proteins, II) subtractive analysis to exclude human homologs and III) qualitative characterization of probable targets essential for the growth of C. botulinum. A flowchart of the method used in this study is given in Figure 1 .
Stage I: Mining of essential proteins
The mining of essential proteins included the following analysis.
Chokepoint proteins (CP):
Chokepoint proteins (enzymes) from C. botulinum and human host (labeled with A) were identified individually using Chokepoint Reaction Finder of BioCyc database [8] . The identical CP between human and C. botulinum was disqualified to avoid cross targeting and CP unique to C. botulinum (labeled with A1) was retained for further analysis. These proteins were further confined by their related enzymatic reactions (labeled with A2) in the KEGG database [9].
Plasmid proteins:
Plasmid proteins of C. botulinum (labeled with B) were retrieved using NCBI [10].
Pathway proteins:
Metabolic pathways in C. botulinum and human host (labeled with C) were obtained independently from the KEGG database [9] and subsequently compared to identify proteins present in distinct pathways of pathogens (labeled with C1) and shared pathways of pathogen and host (labeled with C2).
Virulence proteins:
Virulence factors formerly reported from C. botulinum A str. ATCC 3502 (serotype A) was retrieved from the Virulence Factors Database (VFDB) [11] and scientific literature (labeled with D1). These proteins were manually examined for their existence in human pathways and proteins missing in the host were selected (labeled with D2).
Resistance genes and protein network:
Orthologs of antibiotic resistance genes (such as gyrA, gyrB, rpoB, tetM and catD) in C. botulinum was obtained from the NCBI (labeled with E). The high confidence interactors (STRING score > 0.9) for resistance protein in C. botulinum were observed through STRING 10.0 [12] and the interactors absent in human pathways (labeled with E1) was selected for further analysis.
Stage II: Subtractive channel of analysis
The collected proteins (labeled with A-E) were aligned with each other, and the projected unique proteins were passed through a series of subtractive analysis to predict possible drug targets in C. botulinum.
Human non-homology analysis:
Proteins that are non-homologous to human (labeled with F) were filtered using BLASTp search against the non-redundant database of H. sapiens with E-value of 0.005.
Essentiality analysis:
The identified non-homologous proteins were searched against the Database of Essential Genes (DEG) [13] with E-value of <0.0001 and the significant hits were retained (labeled with G).
Anti-target non-homology analysis:
The identified essential proteins were filtered against the antitargets (essential proteins) of a host (n=210) with E-value of 0.005. The non-homolog proteins in the analysis were retained (labeled with H).
Gut flora non-homology analysis:
The identified anti-targets were filtered against the proteins of human gut microbiota (n=66) using BLASTp with E-value of <0.0001 and sequence pairs with <50%. The shortlisted targets (labeled with I) were retained for qualitative characterization in stage III.
Stage III: Qualitative characterization of the shortlisted targets
The shortlisted targets (labeled with I) were characterized through cellular localization, broad spectrum, interactome, functionality, and druggability analysis.
Cellular localization analysis:
Finding the protein location is significant to predict possible vaccine antigen candidates (surface proteins) and probable drug candidates (inner membrane and cytoplasmic proteins) in bacteria. The location of the shortlisted targets was predicted using Uniprot 
Broad-spectrum target analysis:
BLASTp search against the pathogenic strains (n=223) with an expected threshold value of 0.005 were performed to predict broadspectrum targets in C. botulinum. The shortlisted candidates were further mapped to Cluster of Orthologous Groups of proteins (COG) [18] resulting homologs in other pathogenic bacteria.
©Biomedical Informatics (2019) Table 1 : Drug target identification using subtractive genomics approach. The 15 potential targets including drug (6) and vaccine (9) candidates, non-similar to human, gut microflora, and anti-targets in the host were predicted in C. botulinum. Cluster of Orthologous Group; Functional categories of COGs: E-Amino acid transport and metabolism; P-Inorganic ion transport and metabolism; C-Energy production and conversion; O-Posttranslational modification, protein turnover, chaperones; I-Lipid metabolism; G-Carbohydrate transport and metabolism; Q-Secondary metabolites biosynthesis, transport and catabolism; L-DNA Replication, recombination, and repair; K-Transcription; J-Translation, ribosomal structure and biogenesis; S-Function unknown. 
Functionality analysis:
The function of the hypothetical proteins from the list of shortlisted targets was predicted using INTERPROSCAN [33].
Druggability analysis:
Druggability of the shortlisted targets was analyzed using BLASTp search against the DrugBank 3.0 [20] with an e-value of 10 -5 . This is crucial to identify targets tested by FDA approved drugs. Targets non-homologous to the targets of the DrugBank were labeled as 'novel' targets.
Results and discussion: Mining of essential proteins Chokepoint protein (CP):
A total of 810 chokepoint reactions, including producing (325), consuming (305), and concurrently producing and consuming (180) from C. botulinum were generated ( Table 1 
Plasmid protein:
A total of 18 plasmid proteins from C. botulinum were retrieved using the NCBI databases (Table 1) . Plasmids might play a key role in the adaptability of microbes by providing antibiotic resistance against a wide range of antibiotics and hence be a valuable drug target [22].
Pathway protein:
A comparative metabolic pathway analysis of H. sapiens (280 pathways) and C. botulinum (92 pathways) revealed 23 distinct (present in C. botulinum and absent in H. sapiens) and 59 shared (present in both host and pathogen) pathways (Table 1 ). The associated proteins from distinct (325) and shared pathways (906) were further collected and the proteins common to C. botulinum and human host pathway were omitted to avoid cross targeting in this study. This approach includes the targeting of many specific highpriority pathways for the expansion of multi-drug resistance among pathogenic bacteria [23].
Virulence proteins:
A total of 36 virulence proteins from Virulence Factors Database (9), literature (16) , and proteolytic group I (11), associated with pathogenicity [24] were collected and excluding the repeats, 33 unique proteins absent in human pathways were selected (Table 1) . Virulence factors expressed through bacteria are vital for the survival and growth of pathogenic bacteria and hence can be a valuable drug targets.
Resistance genes and protein network:
Network analysis disclosed 107, 78, 33, and 30 associated interactors for orthologs of rpoB, tetM, gyrA, gyrB antibiotic resistance genes, respectively. Next, a total of 152 interactors absent in human pathways were selected which can be a good target (Table 1) . In this study, no interactors were observed for catD resistance genes.
Subtractive channel of analysis Human non-homologous:
Potential drug targets homologous to host could harmfully affect the host metabolism. Thus, avoiding proteins homologous to host is considered as the leading step in the identification of good drug targets [25] . In this study, qualified datasets from chokepoint protein, plasmid protein, pathway protein, virulence factors, and resistance gene analysis were subjected to non-homology analysis. A total of 1729 proteins were used for homology search and 893 non-homologous proteins were selected (Table 1) .
Essentiality:
The potential drug target must be a crucial protein for the survival of the pathogen [25] . Out of 893 non-homologous proteins, 633 proteins were aligned significantly to Database of Essential Genes (DEG) and were considered as essential proteins for the survival of the pathogen (Table 1 ). The non-aligned 260 proteins were excluded from this analysis.
Anti-target non-homologous:
Protein non-homologous to anti-targets (human essential proteins) is endorsed as drugs inhibiting such targets may interfere with host metabolism triggering severe toxic effects in the host [26] . In this analysis, 633 essential proteins were undergoing a homology search and homologous proteins with anti-target of the host were eliminated, whereas 483 non-homologous proteins were retained for further analysis (Table 1) .
Gut flora non-homologous:
The human host co-evolved with a gut microflora that plays an important role in the absorption of poorly digestible dietary components, vitamin synthesis, and degradation of xenobiotics [27, 28] . Gut microbiota also play a key role in human health by providing resistance to colonization of pathogens and opportunistic bacteria [28, 29] . Therefore, deterioration of the gastrointestinal microbiota population may lack of first line of defense against invading bacteria and may also deal with the deficiency of nutrients in the host [28] . Anti-target non-homologous 483 proteins were undergoing a homology search and 18 gut flora non-homologous proteins were separated. Finally 15 potential targets were shortlisted after removing the redundancy (Table 1 & Table 2 ).
Qualitative characterization of the potential drug targets: Cellular localization:
In this study, we observed the cellular localization of proteins in cytoplasm (6 proteins), membrane (5 proteins), outer membranebounded periplasmic space (3 proteins) and extracellular (1 protein). Proteins that are located in the cytoplasm could be used as drug targets, whereas extracellular and membrane bound proteins are appropriate for vaccine targets [30] .
Broad spectrum: Alignment of proposed targets with medically vital myco bacterial species and other bacterial pathogens facilitates the assessment of broad-spectrum antibiotics that attack a wide range of bacteria. The shortlisted targets were exposed to Cluster of Orthologous Groups of proteins (COG) hunt to identify homologs in other pathogenic bacteria and we observed four targets homologous to more than 75 pathogens and hence are considered as broad spectrum candidates.
Interactome analysis:
A total 14 shortlisted targets were found to be interacting with different C. botulinum strains and protein CBO0881 has maximum 50 interactors. Target with higher interactors was considered as metabolically important active protein, and hence could be used as good drug target [31].
Functionality analysis:
We did not observe any hypothetical proteins from the list of shortlisted targets and hence this step was excluded from this study.
Druggability analysis:
The druggability of the proposed targets was evaluated by sequence similarity search against the targets from DrugBank [20] (Table 3) . Drug target, CBO2715 is found to be homologous with DrugBank targets P26394, Q9HU21, O06330 and O52806 with their corresponding drugs DB02549, DB01694, DB04530 and DB01643, respectively. Remaining drug targets with no homology were differentiated as novel targets (Table 1 & Table 3 ), which require further experimental validation.
Conclusion:
In this study, we identified new targets, including drug and vaccine in C. botulinum using subtractive genomic approach. Identified targets were initially confirmed for their role in the survival of the C. botulinum. The downstream analysis includes non-similarity to gut flora proteins, and anti-targets in the host to predict highconfidence drug targets. Proposed targets were found to be an ideal broad-spectrum candidate, whereas interactome analysis highlighted the functional importance of many query targets. The adopted approach has the potential to be used as a general method for target identification and hence the proposed 15 targets might be used in drug discovery program.
